BioMarin Announces Third Quarter 2022 Year-over-Year Total R

VOXZOGO® $48 Million Contribution in the Quarter Results in BioMarin Raising Full-year 2022 VOXZOGO Net Product Revenue Guidance to Between $140 Million and...

Related Keywords

Japan , United States , Canada , America , Debra Charlesworth , Traci Mccarty , Jean Jacques Bienaim , European Commission , Drug Administration , Biomarin Pharmaceutical Inc , Nasdaq , Replay International Number , International Number , Exchange Commission , Development Expense , Prnewswire Biomarin Pharmaceutical Inc , Radiological Health , European Union Eu Following , Development Portfolio , European Medicines Agency , Biomarin Genzyme , Quarter Results , Biomarin Raising Full Year , Product Revenue Guidance , Prescription Drug User Fee Act , Target Action Date , Commercial Launch , European Union , Following August , Product Revenues Marketed , Net Product , Generally Accepted Accounting Principles , Marin Pharmaceutical , Chief Executive Officer , Total Revenues , Latin America , Middle East , Priority Review Voucher , Product Approvals , Premarket Approval , Product Life Cycle Expansion Opportunities , Hereditary Angioedema , Duchenne Muscular Dystrophy , Investigational New Drug , Year Financial Guidance , Financial Guidance , Canada Dial In Number , Dial In Number , International Dial In Number , Biomarin Pharmaceutical , Net Product Revenues , Administrative Expense , Quarterly Report , Nonqualified Deferred Compensation , Months Ended September , Asset Amortization , Contingent Consideration , Intangible Asset , From Income Taxes , Guidance Year Ending December , Health Care Amp Hospitals , Medical Pharmaceuticals , Pharmaceuticals , Biotechnology , Earnings , Earnings Forecasts Amp Projections ,